Lymphoma and Myeloma 2009: An International Congress on Hematologic Malignancies

22. 10. 2009 - 24. 10. 2009, Waldorf=Astoria, New York, USA

Témata:

Biology of CLL

  • New insights into CLL biology
  • CLL genomics and epigenetics
  • How do we make sense of prognostic markers?

Treatment of CLL

  • Standard treatment of CLL: Evidencebased approaches to untreated and previously treated patients
  • Evidence-based approaches for relapsed treatment
  • Latest results with IMiDS compounds in CLL: How do we manage the rash/flare and what does it mean?
  • Experimental and recently approved novel agents in CLL

Lymphoplasmocytic disorders

  • Waldenstrom’s macroglobulinemia: An update
  • POEMS and Castleman’s disease: Is there a role for novel agents?
  • Amyloidosis: Recent data

Biology of lymphoma

  • The biologic and pathologic basis for the new WHO classification
  • A clinician’s view of the new

WHO classification

  • John Ultmann Award Lecture: Hodgkin’s disease: The past, the present and the future

T cell lymphoma

  • What is the best front line strategy for peripheral T-cell lymphoma: Is there a role of novel agents and transplantation?
  • Have we made progress in the systemic therapy of treating cutaneous T-cell lymphoma?
  • Angioimmunoblastic lymphadenopathy: What is latest in biology and treatment

Mantle cell lymphoma

  • Debate: Should mantle cell be treated aggressively from the onset?

Special concerns in large cell lymphoma

  • Biology and treatment of bulky and mediastinal large cell disease: Is EPOCH really better than CHOP-R with/without radiation?
  • How to prevent and treatment central nervous system disease
  • How can we improve on large cell lymphoma treatment?
  • Genomic/epigenetic targeting of large cell lymphoma: Does it have clinical application?

Low grade lymphoma

  • Is follicular lymphoma curable? If not, has it become a chronic illness?
  • Strategies for low grade lymphoma: How to use prognostic indicators in treatment
  • Lymphomas of the eye: MALT, follicular, large cell
  • Novel agents in low grade lymphoma: More than we can handle?
  • Vaccines redux: Useless or a phoenix?

Hodgkin’s disease: PET scanning

  • Point – Counterpoint: PET scans in Hodgkin’s and non-Hodgkin’s lymphoma
  • The new promise of PET scans
  • The new peril of PET scans

Biology of myeloma

  • Chromosomes, genomics and proteomics as a disease primer
  • Myeloma cell trafficking and mobilization
  • Debate: Does the myeloma stem cell exist? Can we target it for therapeutic purposes?
  • Targeting the cell cycle in myeloma and lymphoma

Clinical pathology and myeloma

  • Measurement of free light and heavy chains: Applications?
  • Minimal residual disease in myeloma: Flow cytometry and molecular techniques
  • The Tower of Babel: Multiple response criteria and the need for a unified standard: Summary of the IMW consensus on response criteria and relevant outcomes
  • Special lecture: Targeted therapy in myeloma
  • Joseph Michaeli Award Lecture: Kinetics, proliferation and novel agents in myeloma: Is autologous transplantaion old hat?

Clinical cases and debates in myeloma

  • First Line Therapy: Poor risk patient
  • Debate: Sequential vs. combination therapy, triplets or more
  • Consolidaton: Good risk patient

Debate: Transplant vs. no transplant

  • First Line Therapy: Non transplant candidate
  • Debate: Bortezomib based vs. IMiD based

Relapse and refractory disease

  • Novel combination therapies for the treatment of relapsed/refractory multiple myeloma: Current phase I/II, combinations using as backbone IMiDs and proteasome inhibitors

Special lecture

  • Highlights from the 2009 International Myeloma Workshop: Are we nearing a cure in myeloma?

Aktivní účast

  • Odevzdávání abstrakt do 23. července 2009

Pasivní účast

Thursday October 22, 2009
8:00 am Welcome
Morton Coleman, MD

CLL Section

8:05 am Introduction
Richard R. Furman, MD

Session I: Biology of CLL
Moderator: John C. Byrd, MD

8:10 am New insights into CLL biology
Speaker invited

8:30 am CLL genomics and epigenetics: What’s on the horizon for clinicians?
John C. Byrd, MD

8:50 am How do we make sense of prognostic markers in CLL when treating patients?
Kanti Rai, MD

9:10 am Panel discussion questions

9:30 am Break

Session II: Treatment of CLL
Moderator: Richard Furman, MD

9:50 am Evidence-based approaches for treatment-naďve patients
Neil Kaye, MD

10:10 am Evidence-based approaches for treating relapsed/refractory patients
Claire Dearden, BSc, MD, FRCP, FPCPath

10:30 am Latest results with IMiDS compounds in CLL: How do we manage the rash and flare?
Asher Chanan-Khan, MD

10:50 am Experimental and recently approved novel agents in CLL
Richard R. Furman, MD

11:10 am Panel discussion

11:20 am Presentation of the best CLL abstract

11:30 am Luncheon Symposium

Session III: Lymphoplasmocytic disorders
Moderator: David J. Wolf, MD

1:30 pm Waldenstrom’s macroglobulinemia: An update
Eva Kimby, MD, PhD

1:50 pm POEMS and Castleman’s disease: Is there a role for novel agents?
Angela Dispenzieri, MD

2:10 pm Amyloidosis: Recent data
Raymond L. Comenzo, MD

2:30 pm Break

Lyphoma Section

2:50 pm Introduction
John P. Leonard, MD

Session IV: Biology of lymphoma
Moderator: Wayne Tam, MD, PhD

2:55 pm The biologic and pathologic basis for the new WHO classification
Randy D. Gascoyne, MD

3:15 pm A clinician’s view of the new WHO classification
Speaker invited

3:35 pm Panel discussion

3:45 pm Presentation of the best Lymphoma abstract

3:55 pm The SASS Foundation for Medical Research Award Ceremony
Francis P. Arena, MD - President & Director of Research for the SASS Foundation
Presentation: John Ultmann Award for Contributions to Lymphoma Research Recipient: Volker Diehl, MD
Presenter: Speaker invited

4:05 pm Hodgkin’s disease: The past, the present and the future
Volker Diehl, MD

4:35 pm Questions and answers

4:45 pm Adjourn

Friday October 23, 2009
8:00 am Welcome
Morton Coleman, MD

8:05 am Introduction
John P. Leonard, MD

Session V: T cell lymphoma
Moderator: Rebecca Elstrom, MD

8:10 am What is the best front line strategy for peripheral T-cell lymphoma: Is there a role of novel agents and transplantation?
Steven Horwitz, MD

8:30 am Have we made progress in the systemic therapy of treating cutaneous T-cell lymphoma?
Steven Rosen, MD

8:50 am Angioimmunoblastic lymphadenopathy: What is latest in biology and treatment?
Rebecca Elstrom, MD

9:10 am Panel discussion and questions

9:20 am Break

Session VI: Mantle cell lymphoma
Moderator: John P. Leonard, MD

9:40 am Debate: Should mantle cell lymphoma be treated aggressively from the onset?
Pro: Brad Kahl, MD
Con: Peter Martin, MD
Moderator: John P. Leonard, MD

10:20 am Discussion and questions

Session VII: Special concerns in large cell lymphoma
Moderator: Thomas Habermann, MD

10:30 am What is the best treat for low stage aggressive lymphomas?
Thomas Habermann, MD

10:50 am How to prevent and treatment central nervous system disease
Steven Bernstein, MD

11:10 am How can we improve on large cell lymphoma treatment?
Bertrand Coiffier, MD

11:30 pm Genomic/epigenetic targeting of large cell lymphoma: Does it have clinical application?
Ari Melnick, MD

11:50 pm Discussion and questions

12:00 pm Luncheon Symposium

Session VIII: Low grade lymphoma
Moderator: Peter McLaughlin, MD

2:00 pm Is follicular lymphoma curable? If not, has it become a chronic illness?
Peter McLaughlin, MD

2:20 pm Strategies for low grade lymphoma: How to use prognostic indicators in treatment
John P. Leonard, MD

2:40 pm Lymphomas of the eye: MALT, follicular, large cell
Morton Coleman, MD

3:00 pm Novel agents in low grade lymphoma: More than we can handle?
Bruce D. Cheson, MD

3:20 pm Vaccines redux: Useless or a phoenix?
Stephen Schuster, MD

3:40 pm Break

Session IX: Hodgkin’s disease:PET scanning
Moderator: Morton Coleman, MD

4:00 pm Point – Counterpoint: PET scans in Hodgkin’s and non-Hodgkin’s lymphoma

The new promise of PET scans
Martin Hutchings, MD, PhD

The new peril of PET scans
Sandra J. Horning, MD
Moderator: Morton Coleman, MD

4:30 pm Discussion and questions

4:45 pm Adjourn

Saturday October 24, 2009
Myeloma Section

8:05 am Introduction
Ruben Niesvizky, MD

Session X: Biology of myeloma
Moderator: Scott Ely, MD, MPH

8:10 am Chromosomes, genomics and proteomics as a disease primer: Is M-SMART smart?
Rafael Fonseca, MD

8:30 am Myeloma cell trafficking and mobilization
Speaker invited

8:50 am Debate: Does the myeloma stem cell exist? Can we target it for therapeutic purposes?
Suzanne Lentzsch, MD, PhD
Carol Ann Huff, MD

9:20 am Targeting the cell cycle in myeloma and lymphoma
Selina Chen- Kiang, PhD

9:40 am Discussion and questions

Session XI: Clinical pathology and myeloma
Moderator: Tomer Mark, MD

9:50 am Measurement of free light and heavy chains: Applications?
Arthur R. Bradwell, MD

10:05 am Minimal residual disease in myeloma: Flow cytometry and molecular techniques: Is MRD clinically relevant?
Speaker invited

10:25 am The Tower of Babel: Multiple response criteria and the need for a unified standard. Summary of the IMW consensus on response criteria and relevant outcomes
S. Vincent Rajkumar, MD

10:45 am Break

11:05 am The SASS Foundation for Medical Research Award Ceremony
Francis P. Arena, MD - President & Director of Research for the SASS Foundation
Presentation: Joseph Michaeli Award for Contributions to Myeloma Research
Recipient: Phillip R. Greipp, MD
Presenter: Rafael Fonseca, MD

11:15 am Sass Foundation/ Michaeli Award Lecture Kinetics, proliferation, and novel agents in myeloma: Is autologous transplantation an anachronism?
Philip R. Greipp, MD

11:45 pm Presentation of the best Myeloma abstract

11:55 pm Special lecture: Targeted therapy in myeloma
Keith Stewart, M.B.Ch.B

12:20 pm Questions

12:25 pm Luncheon Symposium

Session XII: Clinical cases and debates in myeloma
Moderator: Ruben Niesvizky, MD

2:15 pm FIRST LINE THERAPY: Clinical case of poor risk patient
Debate: Sequential therapy vs.combination therapy, triplets or more
Jean-Luc Harousseau, MD (sequential)
Sagar Lonial, MD (combination)

2:45 pm CONSOLIDATION: Clinical case of good risk patient

Debate: Transplant vs. no transplant
Speaker invited (transplant)
Joan Bladée, MD (no transplant)

3:15 pm FIRST LINE THERAPY: Clinical case of non-transplant candidate
Debate: bortezomib based vs. IMiD based
Ruben Niesvizky, MD (bortezomib-based)
Antonio Palumbo, MD (IMiD-based)

Session XIII: Relapse/refractory disease
Moderator: Roger Pearse, MD

3:45 pm SECOND LINE THERAPY: Novel combination therapies for the treatment of relapsed/ refractory multiple myeloma: Current phase I/II combinations using IMiD compounds and proteasome inhibitors as the backbone
James R. Berenson, MD

4:05 pm Questions

Session XIV: Special lecture
Moderator: Morton Coleman, MD, FACP

4:10 pm Highlights from the 2009 International Myeloma Workshop: Are we nearing a cure in myeloma?
Sundar Jagganath, MD

4:40 pm Questions

4:50 pm Adjourn

Kontakt: meetings@imedex.com

Web: http://www.imedex....ements/a115-01.asp

  • Sdílejte na:
    • Facebook
    • Twitter
    • Del.icio.us
    • Digg
    • Google
    • Reddit
    • StumbleUpon
    • Live